BSLN Stock Overview
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
Basilea Pharmaceutica AG Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF34.75|
|52 Week High||CHF55.40|
|52 Week Low||CHF33.95|
|1 Month Change||-0.29%|
|3 Month Change||-27.30%|
|1 Year Change||-29.30%|
|3 Year Change||-33.17%|
|5 Year Change||-21.80%|
|Change since IPO||-65.59%|
Recent News & Updates
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?Sep 20
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)Feb 17
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)Jul 01
Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before LongMar 24
If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%Feb 18
|BSLN||CH Biotechs||CH Market|
Return vs Industry: BSLN underperformed the Swiss Biotechs industry which returned -26% over the past year.
Return vs Market: BSLN underperformed the Swiss Market which returned -1.1% over the past year.
|BSLN Average Weekly Movement||3.0%|
|Biotechs Industry Average Movement||8.4%|
|Market Average Movement||3.5%|
|10% most volatile stocks in CH Market||7.1%|
|10% least volatile stocks in CH Market||1.6%|
Stable Share Price: BSLN is not significantly more volatile than the rest of Swiss stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BSLN's weekly volatility (3%) has been stable over the past year.
About the Company
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia.
Basilea Pharmaceutica AG Fundamentals Summary
|BSLN fundamental statistics|
Is BSLN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BSLN income statement (TTM)|
|Cost of Revenue||CHF77.80m|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Feb 13, 2024
|Earnings per share (EPS)||4.69|
|Net Profit Margin||32.11%|
How did BSLN perform over the long term?See historical performance and comparison